Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Rini, Brian I.; Plimack, Elizabeth R.; Stus, Viktor; Gafanov, Rustem; Hawkins, Robert; Nosov, Dmitry; Pouliot, Frederic; Alekseev, Boris; Soulieres, Denis; Melichar, Bohuslav; Vynnychenko, Ihor; Kryzhanivska, Anna; Bondarenko, Igor; Azevedo, Sergio J.; Borchiellini, Delphine; Szczylik, Cezary; Markus, Maurice; McDermott, Raymond S.; Bedke, Jens; Tartas, Sophie; Chang, Yen-Hwa; Tamada, Satoshi; Shou, Qiong; Perini, Rodolfo F.; Chen, Mei; Atkins, Michael B.; Powles, Thomas

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Autor(en):

Rini, Brian I.; Plimack, Elizabeth R.; Stus, Viktor; Gafanov, Rustem; Hawkins, Robert; Nosov, Dmitry; Pouliot, Frederic; Alekseev, Boris; Soulieres, Denis; Melichar, Bohuslav; Vynnychenko, Ihor; Kryzhanivska, Anna; Bondarenko, Igor; Azevedo, Sergio J.; Borchiellini, Delphine; Szczylik, Cezary; Markus, Maurice; McDermott, Raymond S.; Bedke, Jens; Tartas, Sophie; Chang, Yen-Hwa; Tamada, Satoshi; Shou, Qiong; Perini, Rodolfo F.; Chen, Mei; Atkins, Michael B.; Powles, Thomas

Tübinger Autor(en):

Bedke, Jens

Erschienen in:

New England Journal of Medicine (2019), Bd. 380, H. 12, S. 1116-1127

Verlagsangabe:

Massachusetts Medical Soc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1056/NEJMoa1816714

ISSN:

1533-4406